Abstract
Background Excessive post-surgical opioid prescribing is contributing to the growing opioid crisis. Prescribing practices are modifiable, yet data to guide appropriate prescription of opioids at surgical discharge remain sparse. We therefore aimed to evaluate the factors associated with opioid consumption following discharge from surgery.
Methods We performed an international, prospective, multicentre, cohort study between 4 April 2022 and 4 September 2022 among adult patients undergoing common general, orthopaedic, gynaecological and urological operations, with follow-up 7 days after hospital discharge. The primary outcome measure was the quantity of prescribed and consumed opioids in oral morphine equivalents (OMEs). Descriptive and multivariable analyses were performed to investigate factors associated with OME quantities prescribed and consumed.
Findings This analysis includes 4273 patients across 144 hospitals in 25 countries. Overall, 30.7% (n=1311) of patients were prescribed opioids at discharge. For those prescribed opioids, a median of 100 OMEs (IQR 60 - 200) were prescribed but only a median of 40 OMEs (IQR 7.5 - 100; p<0.001) were consumed at follow-up 7 days after discharge. After risk-adjustment, an increased amount of opioids prescribed was independently associated with increased opioid consumption in the follow up period (β = 0.33, 95% CI 0.31 - 0.34, p<0.001), and side-effects. The risk of prescribing more opioids than patients’ consumed increased as quantities of opioids prescribed exceeded 100 OMEs, independent of patient comorbidity, procedure, and pain.
Interpretation Patients were prescribed more than twice the quantity of opioids they consumed in the 7 days following discharge from surgery. Prescription quantity was associated with increased consumption of opioids even after adjusting for pain levels, suggesting that prescribing practice is a modifiable risk factor to curtailing excessive opioid consumption. Current quantities of opioids provided are in excess of patient needs and may contribute to increasing community opioid use and circulation.
Funding Maurice and Phyllis Paykel Trust, Surgical Research Funds University of Newcastle.
Evidence before this study Opioids are frequently prescribed at discharge after surgery, yet little is understood about the drivers of opioid use in this setting. We conducted a literature search between November 2020 and February 2021 for studies reporting on opioid prescription and consumption after discharge from surgery. We used the search terms “opioid”, “surgery”, “discharge”, and applied no language or date restrictions. Several global studies examined variations in opioid prescribing, however, little data exists specific to surgical practice. Several single centre and retrospective surgical series examined the independent role of prescribing practice on opioid consumption; however, these data are not globally generalisable. A recent systematic review and meta-analysis suggests the analgesic efficacy of opioids in the post-surgical-discharge setting may be overstated, exposing populations to their adverse events with minimal improvements in pain management. Given the lack of global, generalisable, high-quality data in the setting of post-surgical discharge, practice is predominantly guided by clinician preferences, dogma, and health system cultures.
Added value of this study This prospective, international, cohort study provides high-quality, cross-specialty, patient-reported data after surgical discharge following a variety of common surgical procedures, including both emergency and elective, minor and major, surgeries. This study includes 4273 patients from 144 centres across 25 countries. Among those prescribed opioids, the median prescription of opioids was 100 oral morphine equivalents (OMEs; IQR 60 - 200) and median consumption at 7-days follow-up was 40 OME (IQR 7.5 - 100; p<0.001). Prescription and consumption of opioids varied by specialty, but predominantly prescribed quantities were in excess of what was consumed by patients within the first 7 days after hospital discharge. This was particularly evident for patients prescribed over 100 OMEs. The quantity of opioids prescribed was associated with higher patient-reported opioid consumption at surgical discharge, and increasing quantities of opioids prescribed and consumed were associated with increased risk of opioid-related harm.
Implications of all the available evidence Overprescribing opioids increases absolute consumption of opioids, even after adjusting for patients’ pain levels, with an associated increase in opioid-related side effects. The value of opioids after surgical discharge has been questioned, and when prescribed, are frequently in excessive quantities. Prescribing practices need to be altered with a more cautious approach to prescribing opioids after surgical procedures. When required, quantities should be rationalised to minimise opioid-related harm, community circulation of opioids, dependence, misuse, and overdose. Our study bridges a crucial knowledge gap and offers guidance on opioid prescribing across a range of common surgical procedures.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://bmjopen.bmj.com/content/12/11/e063577
Funding Statement
OPERAS has received funding from the Maurice and Phyllis Paykel Trust (Ref: 213122) and Surgical Research Funds, University of Newcastle.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approvals were obtained according to the requirements at each participating centre and verified by the central steering committee. The Hunter New England Human Research Ethics Committee (2021/ETH11508) approved the protocol as the lead site.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflicts of interest None to declare.
Funding source OPERAS has received funding from the Maurice and Phyllis Paykel Trust (Ref: 213122) and Surgical Research Funds, University of Newcastle.
Data Availability
All data produced in the present study are available upon reasonable request to the authors contingent on ethical approval(s).
